SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...
Lake Oswego, OR - January 08, 2026 - PRESSADVANTAGE - At Tersigni Vision, a growing number of patients are asking ...
SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...
AI-powered diagnostics, smart lenses, and connected wearables are redefining global eye health by enabling early detection, ...
Phase I human study and preclinical evaluations of OcuRing™-K showed no treatment-related safety concerns, supporting ...
The stock is currently trading 21.12% above its 20-day simple moving average (SMA) and 12.9% above its 100-day SMA, ...
ST. LOUIS, MO - January 23, 2026 - PRESSADVANTAGE - Brinton Vision today announced the release of its new article, ...
The BIM-IOL is designed to be implanted during cataract surgery, tackling IOP while restoring vision, and SpyGlass is also ...
SightMD is proud to welcome two outstanding eye care professionals, William Boozan, MD and Tracey Rosenlicht, OD, to its growing network of providers. Their combined expertise enhances SightMD's ...
The Holland Foundation for Sight Restoration, the only foundation in the world created to address a critical unmet medical ...
PainReform Ltd. is a Tel Aviv-based, clinical-stage specialty pharmaceutical company that reformulates established therapeutics for post-operative pain management using sustained-release drug-delivery ...
Hosted on MSN
Myth busting: the truth about Cataracts
Comments attributed to Dr Moemen Elnawawy, ophthalmic surgeon for CHEC. Cataracts are one of the most common reasons for vision loss in adults – but they’re also one of the most misunderstood eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback